Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come
Shares of biotechnology company Anika Therapeutics soared to an all-time high Wednesday after the company said the FDA had approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Shares of biotechnology company Anika Therapeutics Inc. (NASDAQ: ANIK) soared to an all-time high Wednesday after the company said the U.S. Food and Drug Administration (FDA) had approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee.
The company said the drug, called Monovisc, will be marketed by DePuy Synthes, a unit of Johnson & Johnson (NYSE: JNJ). Anika will receive a $5 million payment when DePuy Synthes makes its first sale of the drug. It will receive additional payments and royalty fees in the future as well.
Monovisc treats pain and improves joint mobility. It is injected into the synovial fluid of a patient’s knee. It has been available since 2008 in Europe, Canada, the United Kingdom and other countries in Europe, the Middle East and Asia.
The shares were up $15.84, or 46%, to $50.31, after hitting an intraday peak of $51.95 right after the open. Formed in 1992, Anika has been growing steadily in recent years, with sales hitting $71 million in 2012, up from $40 million in 2009.
Fourth-quarter results for 2013 are due after Wednesday’s close, with analysts expecting $0.42 a share in earnings, unchanged from a year ago, on revenue of $21.1 million, down slightly.
Contact [email protected] for any questions or corrections.
Charley Blaine is a veteran financial journalist. He wrote about markets and edited personal finance articles at MSN Money. He was editor of Family Money magazine and business/financial editor at The Times-Picayune and a Money reporter at USA Today.
